Q2 2019 Deals Industry Insights: Megadeals in many sectors reflect interest in increasing scale
By John Potter, US Deals Sector Leader @johndpotter Anyone who says summer is slow for business isn’t watching M&A, and …
Global pharma and life sciences deals insights: Year-end 2018
A year end look at M&A in the Pharmaceutical and Life Sciences sector, and new deals setting the stage for a strong start to 2019. By Glenn …
PwC Deals in the AIRA Journal
For years, Long-Term Acute Care Hospitals (LTACHs) have been at the center of a transformation of how healthcare providers care for patients and are reimbursed for services. Now, as new patient care …
How the FASB’s new definition of a business impacts pharma/life sciences deals
By Shurjo Sen, PwC Deals Partner, Accounting Advisory In January 2017, the Financial Accounting Standards Board (FASB) issued new guidance …
Restructuring trends: What did we see in 2017 and what lies ahead for 2018?
By Steve Fleming, US Crisis and Restructuring Leader, PwC Deals In our recently released paper, Bankruptcy and Restructuring: 2017 in Review and …
Capturing deal value in Healthcare Services
By Angus Buchanan, Principal, PwC’s Deals Practice It’s no secret the healthcare market has undergone a wave of M&A activity over the past decade as service providers …
PwC’s Mid-year Deals Outlook: Slow start, but still active
Can we expect a dealmaking turnaround in 2016? Dealmaking significantly subsided in the first half of 2016 following a very active year. Equity market volatility, …
